Company
Heidelberg Engineering
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
16
510(k), De Novo and PMA
Device trials
19
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
3
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Heidelberg Engineering, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Heidelberg Engineering.
Latest FDA decisions
The 8 newest of 16 since 2015.
- ANTERION510(k)
K261019 · Decided Sep 11, 2026 · 168 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
K253837 · Decided May 7, 2026 · 157 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
K250868 · Decided May 12, 2025 · 49 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
13 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Heidelberg Engineering ANTERION Software Comparison StudyActive, not recruiting
NCT06657716 · 60 participants (planned) · Start Oct 2, 2024 · Primary completion Dec 2026
Device: ANTERION investigational · For: Eyes With Normal Anterior Segment; Eyes With Abnormal Anterior Segment
Sites: Wilmar, Minnesota
- High Resolution Imaging OCT StudyRecruiting
NCT07338461 · 97 participants (planned) · Start Mar 13, 2026 · Primary completion Dec 30, 2026
Device: Autofluorescence Imaging; Infrared reflectance imaging and 2 more · For: Normal Eyes; Age Related Macular Degeneration; Diabetic Retinopathy and 1 more
Sites: Milan, Italy
NCT04961398 · 9 participants · Start Jun 21, 2021 · Primary completion Jun 24, 2021
Device: OCT imaging · For: Normal Eyes
Sites: Franklin, Massachusetts
16 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-3215-2026 · Started Aug 6, 2026 · Posted by FDA Sep 18, 2026
Reason given: Wheels may come loose when module is being pushed or pulled during movement or transportation, affecting stability of the stand. The stand may tip over as a result. Falling stand may cause impact or crushing injuries, particularly to the feet, legs, hands or arms of the operator or nearby persons.
Cause as FDA categorized it: Component design/selection · Device type: Tomography, Optical Coherence (OBO)
- SPECTRALIS with HEYEX2 image management system. a non-contact ophthalmic diagnostic imaging device.Terminated
Z-2437-2019 · Started Jul 3, 2019
Reason given: Error in the default configuration which could lead to the incorrect display of patient master data.
Cause as FDA categorized it: Under Investigation by firm · Device type: Tomography, Optical Coherence (OBO)
Z-1535-2018 · Started Dec 8, 2017
Reason given: FDA notified Heidelberg Engineering that a 510(k) clearance is needed for the SPECTRALIS Widefield OCT feature, and, on November 27, 2017, Heidelberg Engineering submitted a new 510(k) for this feature. FDA has asked Heidelberg Engineering to instruct customers not to use the Widefield OCT software feature on the...
Cause as FDA categorized it: No Marketing Application · Device type: Tomography, Optical Coherence (OBO)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.